{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:14:36Z","timestamp":1794640476227,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tuberous sclerosis complex (TSC) is an autosomal dominant inherited disease characterized by lesions that involve multiple organs. Interdisciplinary management at individual facilities needs to be coordinated to treat multiple organ systems. We hypothesized that the number of patients, opportunities for patients to undergo examinations, and opportunities for patients to be treated would increase after establishment of a TSC board (TB) in our hospital. From August 1979 to August 2017, 76 patients were studied. We established the TB in our hospital in 2014. We divided the patients into the pre-TB group and post-TB group. Patients consisted of 33 females and 43 males (mean age, 18.7 years; median age, 15 years). The follow-up period was 2 to 457 months (mean, 51.6 months; median, 24.5 months). Twenty-four patients were in the pre-TB group, and 52 were in the post-TB group. Regular follow-up (p\u2009&lt;\u20090.001), younger age (p\u2009=\u20090.002), opportunities for patients to undergo examinations, opportunities for patients to receive neurological treatment (p\u2009&lt;\u20090.001), and mammalian target of rapamycin (mTOR) inhibitor usage (p\u2009=\u20090.041) were significantly higher in the post-TB group. The radial relationship around the axis of TSC coordinators may be the key to interdisciplinary management of TSC.<\/jats:p>","DOI":"10.1038\/s41598-018-35168-y","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T12:38:20Z","timestamp":1541594300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Establishment of a Regional Interdisciplinary Medical System for Managing Patients with Tuberous Sclerosis Complex (TSC)"],"prefix":"10.1038","volume":"8","author":[{"given":"Ayataka","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Okanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ogai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Obana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Masui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Enoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"35168_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0553-5","volume":"12","author":"JC Kingswood","year":"2017","unstructured":"Kingswood, J. C. et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis 12, 2, https:\/\/doi.org\/10.1186\/s13023-016-0553-5 (2017).","journal-title":"Orphanet J Rare Dis"},{"key":"35168_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/jmg.26.1.28","volume":"26","author":"JR Sampson","year":"1989","unstructured":"Sampson, J. R., Scahill, S. J., Stephenson, J. B., Mann, L. & Connor, J. M. Genetic aspects of tuberous sclerosis in the west of Scotland. J Med Genet 26, 28\u201331 (1989).","journal-title":"J Med Genet"},{"key":"35168_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(05)60291-7","volume":"352","author":"PJ Morrison","year":"1998","unstructured":"Morrison, P. J., Shepherd, C. H., Stewart, F. J. & Nevin, N. C. Prevalence of tuberous sclerosis in UK. Lancet (London, England) 352, 318\u2013319 (1998).","journal-title":"Lancet (London, England)"},{"issue":"9","key":"35168_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/iju.13390","volume":"24","author":"Mari Wataya-Kaneda","year":"2017","unstructured":"Wataya-Kaneda, M. et al. Tuberous sclerosis complex: Recent advances in manifestations and therapy. Int J Urol, https:\/\/doi.org\/10.1111\/iju.13390 (2017).","journal-title":"International Journal of Urology"},{"key":"35168_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0387-7604(81)80007-1","volume":"3","author":"K Ohno","year":"1981","unstructured":"Ohno, K., Takeshita, K. & Arima, M. Frequency of tuberous sclerosis in San-in district (Japan) and birth weight of patients with tuberous sclerosis. Brain & development 3, 57\u201364 (1981).","journal-title":"Brain & development"},{"key":"35168_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup, H. & Krueger, D. A. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatric neurology 49, 243\u2013254, https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.08.001 (2013).","journal-title":"Pediatric neurology"},{"key":"35168_CR7","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/s0140-6736(05)78872-3","volume":"351","author":"FJ O\u2019Callaghan","year":"1998","unstructured":"O\u2019Callaghan, F. J., Shiell, A. W. & Osborne, J. P. & Martyn, C. N. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet (London, England) 351, 1490, https:\/\/doi.org\/10.1016\/s0140-6736(05)78872-3 (1998).","journal-title":"Lancet (London, England)"},{"key":"35168_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/jhg.2013.3","volume":"58","author":"Y Niida","year":"2013","unstructured":"Niida, Y. et al. Mutational analysis of TSC1 and TSC2 in Japanese patients with tuberous sclerosis complex revealed higher incidence of TSC1 patients than previously reported. J Hum Genet 58, 216\u2013225, https:\/\/doi.org\/10.1038\/jhg.2013.3 (2013).","journal-title":"J Hum Genet"},{"key":"35168_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s1470-2045(07)70411-4","volume":"9","author":"J Jozwiak","year":"2008","unstructured":"Jozwiak, J., Jozwiak, S. & Wlodarski, P. Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 9, 73\u201379, https:\/\/doi.org\/10.1016\/s1470-2045(07)70411-4 (2008).","journal-title":"Lancet Oncol"},{"key":"35168_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00508-015-0758-y","volume":"127","author":"S Samueli","year":"2015","unstructured":"Samueli, S. et al. Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management. Wiener klinische Wochenschrift 127, 619\u2013630, https:\/\/doi.org\/10.1007\/s00508-015-0758-y (2015).","journal-title":"Wiener klinische Wochenschrift"},{"key":"35168_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.yebeh.2018.03.012","volume":"83","author":"P Both","year":"2018","unstructured":"Both, P. et al. Tuberous sclerosis complex: Concerns and needs of patients and parents from the transitional period to adulthood. Epilepsy & behavior: E&B 83, 13\u201321, https:\/\/doi.org\/10.1016\/j.yebeh.2018.03.012 (2018).","journal-title":"Epilepsy & behavior: E&B"},{"key":"35168_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejpn.2015.11.011","volume":"20","author":"C Kingswood","year":"2016","unstructured":"Kingswood, C. et al. The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: A retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Eur J Paediatr Neurol 20, 296\u2013308, https:\/\/doi.org\/10.1016\/j.ejpn.2015.11.011 (2016).","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"35168_CR13","doi-asserted-by":"publisher","first-page":"e20164040","DOI":"10.1542\/peds.2016-4040","volume":"140","author":"Peter E. Davis","year":"2017","unstructured":"Davis, P. E. et al. Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants. Pediatrics, https:\/\/doi.org\/10.1542\/peds.2016-4040 (2017).","journal-title":"Pediatrics"},{"key":"35168_CR14","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1177\/0883073817737446","volume":"32","author":"A Jeong","year":"2017","unstructured":"Jeong, A., Nakagawa, J. A. & Wong, M. Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex. Journal of child neurology 32, 1092\u20131098, https:\/\/doi.org\/10.1177\/0883073817737446 (2017).","journal-title":"Journal of child neurology"},{"key":"35168_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2133.2008.08677.x","volume":"159","author":"GF Hofbauer","year":"2008","unstructured":"Hofbauer, G. F. et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. The British journal of dermatology 159, 473\u2013475, https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08677.x (2008).","journal-title":"The British journal of dermatology"},{"key":"35168_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000448293","volume":"134","author":"JC Kingswood","year":"2016","unstructured":"Kingswood, J. C. et al. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Nephron 134, 51\u201358, https:\/\/doi.org\/10.1159\/000448293 (2016).","journal-title":"Nephron"},{"key":"35168_CR17","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz, D. N. et al. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS One 11, e0158476, https:\/\/doi.org\/10.1371\/journal.pone.0158476 (2016).","journal-title":"PLoS One"},{"issue":"10","key":"35168_CR18","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.14964","volume":"32","author":"D.N. Franz","year":"2018","unstructured":"Franz, D. N. et al. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. Journal of the European Academy of Dermatology and Venereology: JEADV, https:\/\/doi.org\/10.1111\/jdv.14964 (2018).","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"35168_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s0140-6736(12)61767-x","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler, J. J. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 381, 817\u2013824, https:\/\/doi.org\/10.1016\/s0140-6736(12)61767-x (2013).","journal-title":"Lancet (London, England)"},{"key":"35168_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00467-017-3806-1","volume":"33","author":"JJ Bissler","year":"2018","unstructured":"Bissler, J. J. et al. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatric nephrology (Berlin, Germany) 33, 101\u2013109, https:\/\/doi.org\/10.1007\/s00467-017-3806-1 (2018).","journal-title":"Pediatric nephrology (Berlin, Germany)"},{"key":"35168_CR21","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/s0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French, J. A. et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet (London, England) 388, 2153\u20132163, https:\/\/doi.org\/10.1016\/s0140-6736(16)31419-2 (2016).","journal-title":"Lancet (London, England)"},{"key":"35168_CR22","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/dmcn.12537","volume":"56","author":"AC Jansen","year":"2014","unstructured":"Jansen, A. C. Careful clinical observation continues to improve understanding of the phenotype in individuals with tuberous sclerosis complex. Developmental medicine and child neurology 56, 1134\u20131135, https:\/\/doi.org\/10.1111\/dmcn.12537 (2014).","journal-title":"Developmental medicine and child neurology"},{"key":"35168_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1053\/ajkd.1998.v31.pm9631851","volume":"31","author":"R Torra","year":"1998","unstructured":"Torra, R. et al. Facilitated diagnosis of the contiguous gene syndrome: tuberous sclerosis and polycystic kidneys by means of haplotype studies. American journal of kidney diseases: the official journal of the National Kidney Foundation 31, 1038\u20131043 (1998).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"35168_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1071\/AH070330","volume":"31","author":"RL Jessup","year":"2007","unstructured":"Jessup, R. L. Interdisciplinary versus multidisciplinary care teams: do we understand the difference? Australian Health Review 31, 330 (2007).","journal-title":"Australian Health Review"},{"key":"35168_CR25","doi-asserted-by":"publisher","first-page":"e015236","DOI":"10.1136\/bmjopen-2016-015236","volume":"7","author":"C Shepherd","year":"2017","unstructured":"Shepherd, C. et al. Understanding the health economic burden of patients with tuberous sclerosis complex (TSC) with epilepsy: a retrospective cohort study in the UK Clinical Practice Research Datalink (CPRD). BMJ Open 7, e015236, https:\/\/doi.org\/10.1136\/bmjopen-2016-015236 (2017).","journal-title":"BMJ Open"},{"key":"35168_CR26","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/13696998.2016.1199432","volume":"19","author":"JC Kingswood","year":"2016","unstructured":"Kingswood, J. C. et al. The economic burden of tuberous sclerosis complex in the UK: A retrospective cohort study in the Clinical Practice Research Datalink. J Med Econ 19, 1087\u20131098, https:\/\/doi.org\/10.1080\/13696998.2016.1199432 (2016).","journal-title":"J Med Econ"},{"key":"35168_CR27","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0883073815575364","volume":"30","author":"AM Rentz","year":"2015","unstructured":"Rentz, A. M. et al. Caring for Children With Tuberous Sclerosis Complex: What Is the Physical and Mental Health Impact on Caregivers? J Child Neurol 30, 1574\u20131581, https:\/\/doi.org\/10.1177\/0883073815575364 (2015).","journal-title":"J Child Neurol"},{"key":"35168_CR28","doi-asserted-by":"publisher","unstructured":"Covelli, V., Raggi, A., Paganelli, C. & Leonardi, M. Family members and health professionals\u2019 perspectives on future life planning of ageing people with Down syndrome: a qualitative study. Disabil Rehabil, 1\u20138, https:\/\/doi.org\/10.1080\/09638288.2017.1362595 (2017).","DOI":"10.1080\/09638288.2017.1362595"},{"key":"35168_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pediatrneurol.2017.05.014","volume":"76","author":"Clara W.T. Chung","year":"2017","unstructured":"Chung, C. W. T. et al. Early Detection of Tuberous Sclerosis Complex: An Opportunity for Improved Neurodevelopmental Outcome. Pediatric neurology, https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.05.014 (2017).","journal-title":"Pediatric Neurology"},{"key":"35168_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejpn.2009.03.003","volume":"14","author":"R Bombardieri","year":"2010","unstructured":"Bombardieri, R., Pinci, M., Moavero, R., Cerminara, C. & Curatolo, P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol 14, 146\u2013149, https:\/\/doi.org\/10.1016\/j.ejpn.2009.03.003 (2010).","journal-title":"Eur J Paediatr Neurol"},{"key":"35168_CR31","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/epi.13557","volume":"57","author":"KG Knupp","year":"2016","unstructured":"Knupp, K. G. et al. Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia 57, 1834\u20131842, https:\/\/doi.org\/10.1111\/epi.13557 (2016).","journal-title":"Epilepsia"},{"key":"35168_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","volume":"15","author":"S J\u00f3\u017awiak","year":"2011","unstructured":"J\u00f3\u017awiak, S. et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. European Journal of Paediatric Neurology 15, 424\u2013431, https:\/\/doi.org\/10.1016\/j.ejpn.2011.03.010 (2011).","journal-title":"European Journal of Paediatric Neurology"},{"key":"35168_CR33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1185\/03007995.2012.658907","volume":"28","author":"P Sun","year":"2012","unstructured":"Sun, P. et al. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin 28, 657\u2013663, https:\/\/doi.org\/10.1185\/03007995.2012.658907 (2012).","journal-title":"Curr Med Res Opin"},{"key":"35168_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pediatrneurol.2016.11.003","volume":"68","author":"R Moavero","year":"2017","unstructured":"Moavero, R. et al. Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas. Pediatric neurology 68, 59\u201363, https:\/\/doi.org\/10.1016\/j.pediatrneurol.2016.11.003 (2017).","journal-title":"Pediatric neurology"},{"key":"35168_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/iju.13168","volume":"23","author":"T Hatano","year":"2016","unstructured":"Hatano, T., Chikaraishi, K., Inaba, H., Endo, K. & Egawa, S. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan. International Journal of Urology 23, 833\u2013838 (2016).","journal-title":"International Journal of Urology"},{"key":"35168_CR36","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler, J. J. et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS One 12, e0180939, https:\/\/doi.org\/10.1371\/journal.pone.0180939 (2017).","journal-title":"PLoS One"},{"key":"35168_CR37","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1365-2133.2011.10471.x","volume":"165","author":"M Wataya-Kaneda","year":"2011","unstructured":"Wataya-Kaneda, M., Tanaka, M., Nakamura, A., Matsumoto, S. & Katayama, I. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. The British journal of dermatology 165, 912\u2013916, https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10471.x (2011).","journal-title":"The British journal of dermatology"},{"key":"35168_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2016.04.003","volume":"61","author":"S Jozwiak","year":"2016","unstructured":"Jozwiak, S., Sadowski, K., Kotulska, K. & Schwartz, R. A. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature. Pediatric neurology 61, 21\u201327, https:\/\/doi.org\/10.1016\/j.pediatrneurol.2016.04.003 (2016).","journal-title":"Pediatric neurology"},{"key":"35168_CR39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1586\/17476348.2016.1148603","volume":"10","author":"DH Yates","year":"2016","unstructured":"Yates, D. H. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus. Expert Rev Respir Med 10, 249\u2013260, https:\/\/doi.org\/10.1586\/17476348.2016.1148603 (2016).","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"35168_CR40","doi-asserted-by":"publisher","first-page":"00102","DOI":"10.1183\/23120541.00102-2015","volume":"2","author":"Iris Bassi","year":"2016","unstructured":"Bassi, I. et al. Understanding the priorities for women diagnosed with lymphangioleiomyomatosis: a patient perspective. ERJ open research 2, https:\/\/doi.org\/10.1183\/23120541.00102-2015 (2016).","journal-title":"ERJ Open Research"},{"key":"35168_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40265-016-0552-9","volume":"76","author":"P Curatolo","year":"2016","unstructured":"Curatolo, P. et al. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs 76, 551\u2013565, https:\/\/doi.org\/10.1007\/s40265-016-0552-9 (2016).","journal-title":"Drugs"},{"key":"35168_CR42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.spen.2015.10.006","volume":"22","author":"R Moavero","year":"2015","unstructured":"Moavero, R., Romagnoli, G., Graziola, F. & Curatolo, P. Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex. Seminars in pediatric neurology 22, 282\u2013294, https:\/\/doi.org\/10.1016\/j.spen.2015.10.006 (2015).","journal-title":"Seminars in pediatric neurology"},{"key":"35168_CR43","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.neuron.2014.07.040","volume":"83","author":"G Tang","year":"2014","unstructured":"Tang, G. et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 83, 1131\u20131143, https:\/\/doi.org\/10.1016\/j.neuron.2014.07.040 (2014).","journal-title":"Neuron"},{"key":"35168_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-neuro-080317-061747","volume":"41","author":"KD Winden","year":"2018","unstructured":"Winden, K. D., Ebrahimi-Fakhari, D. & Sahin, M. Abnormal mTOR Activation in Autism. Annual review of neuroscience 41, 1\u201323, https:\/\/doi.org\/10.1146\/annurev-neuro-080317-061747 (2018).","journal-title":"Annual review of neuroscience"},{"key":"35168_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.yebeh.2018.05.014","volume":"85","author":"F Majolo","year":"2018","unstructured":"Majolo, F., Marinowic, D. R., Machado, D. C. & Da Costa, J. C. MTOR pathway in focal cortical dysplasia type 2: What do we know? Epilepsy & behavior: E&B 85, 157\u2013163, https:\/\/doi.org\/10.1016\/j.yebeh.2018.05.014 (2018).","journal-title":"Epilepsy & behavior: E&B"},{"key":"35168_CR46","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/epi.12650","volume":"55","author":"I Marin-Valencia","year":"2014","unstructured":"Marin-Valencia, I., Guerrini, R. & Gleeson, J. G. Pathogenetic mechanisms of focal cortical dysplasia. Epilepsia 55, 970\u2013978, https:\/\/doi.org\/10.1111\/epi.12650 (2014).","journal-title":"Epilepsia"},{"key":"35168_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2015.11.009","volume":"58","author":"AM Comi","year":"2016","unstructured":"Comi, A. M. et al. Leveraging a Sturge-Weber Gene Discovery: An Agenda for Future Research. Pediatric neurology 58, 12\u201324, https:\/\/doi.org\/10.1016\/j.pediatrneurol.2015.11.009 (2016).","journal-title":"Pediatric neurology"},{"key":"35168_CR48","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/088307389801301206","volume":"13","author":"ES Roach","year":"1998","unstructured":"Roach, E. S., Gomez, M. R. & Northrup, H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. Journal of child neurology 13, 624\u2013628, https:\/\/doi.org\/10.1177\/088307389801301206 (1998).","journal-title":"Journal of child neurology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35168-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35168-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35168-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:24:02Z","timestamp":1671621842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35168-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["35168"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35168-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"18 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16747"}}